Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
The number of avoided fractures would be higher in women than in men and would be highest among those in their 70s in the EU and in those ≥ 80 years old in the US compared with the other age groups (Fig. 1a and b).Estimated number of fractures avoided annually, by gender and age, with 100% use of calcium and vitamin D supplementation by adults aged ≥ 50 years in a the European Union and b the United States
Source: Fracture reduction with calcium and vitamin D supplementation. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
2013 []cData provided from WHI investigatorsdResults from data on fracture confirmed by radiographyeA total of 5292 were randomized to four groups: 1306 to calcium and vitamin D, 1343 to vitamin D alone, 1311 to calcium alone, and 1332 to placebo; only the calcium + vitamin D and placebo groups are included herefA total of 150 women were randomized to four groups: 38 to injected vitamin D, 36 to injected vitamin D with oral calcium; 39 to oral vitamin D and calcium, and 37 to control; only the oral vitamin D and calcium and control groups are included heregSDs not reportedCI, confidence interval; NR, not reported; RR, relative risk; SD, standard deviation; Tx, treatment; WHI, Women’s Health Initiative
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Cost-benefit analysis of calcium and vitamin D supplements
Study design awaiting verification · Archives of Osteoporosis · 2019
Original publication title
Cost-benefit analysis of calcium and vitamin D supplements
© The Author(s) 2019
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
Evaluate the cost-effectiveness of calcium/vitamin D supplementation for preventing osteoporotic fractures.
Source: PurposeAbstract: What methods does the paper describe?
A cost-benefit analysis tool was used to estimate the net cost savings from reduced fracture-related hospital expenses if adults with osteoporosis in the EU and US used calcium/vitamin D supplements. A 14% relative risk reduction of fracture with calcium/vitamin D supplementation from a recent systematic review and meta-analysis of randomized, controlled trials was used as the basis for the benefit estimate. Other model inputs were informed by epidemiologic, clinical, and cost data (2016 to 2017) obtained via the medical literature or public databases.
Analyses estimated the total number of avoided fractures and associated cost savings with supplement use. Net cost benefit was calculated by subtracting the supplements’ market costs from those savings.
Source: MethodsAbstract: Summary
If all adults with osteoporosis in the European Union (EU) and United States (US) used calcium and vitamin D supplements, it could prevent more than 500,000 fractures/year in the EU and more than 300,000/year in the US and save approximately €5.7 billion and US $3.3 billion annually.
Source: SummaryAbstract: Electronic supplementary material
The online version of this article (10.1007/s11657-019-0589-y) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
The > 30 million persons in the EU and nearly 11 million in US with osteoporosis experience about 3.9 million and 2.3 million fractures/year and have annual hospital costs exceeding €50 billion and $28 billion. If all persons with osteoporosis used calcium and vitamin D supplements, there would be an estimated 544,687 fewer fractures/year in the EU and 323,566 fewer in the US, saving over €6.9 billion and $3.9 billion; the net cost benefit would be €5,710,277,330 and $3,312,236,252, respectively.
Source: ResultsAbstract: Conclusions
Calcium and vitamin D supplements are highly cost-effective, and expanded use could considerably reduce fractures and related costs. Although these analyses included individuals aged ≥ 50 years, the observed effects are likely driven by benefits observed in those aged ≥ 65 years.
Source: ConclusionsAuthors’ abstract
Summary
If all adults with osteoporosis in the European Union (EU) and United States (US) used calcium and vitamin D supplements, it could prevent more than 500,000 fractures/year in the EU and more than 300,000/year in the US and save approximately €5.7 billion and US $3.3 billion annually.
Purpose
Evaluate the cost-effectiveness of calcium/vitamin D supplementation for preventing osteoporotic fractures.
Methods
A cost-benefit analysis tool was used to estimate the net cost savings from reduced fracture-related hospital expenses if adults with osteoporosis in the EU and US used calcium/vitamin D supplements. A 14% relative risk reduction of fracture with calcium/vitamin D supplementation from a recent systematic review and meta-analysis of randomized, controlled trials was used as the basis for the benefit estimate. Other model inputs were informed by epidemiologic, clinical, and cost data (2016 to 2017) obtained via the medical literature or public databases.
Analyses estimated the total number of avoided fractures and associated cost savings with supplement use. Net cost benefit was calculated by subtracting the supplements’ market costs from those savings.
Results
The > 30 million persons in the EU and nearly 11 million in US with osteoporosis experience about 3.9 million and 2.3 million fractures/year and have annual hospital costs exceeding €50 billion and $28 billion. If all persons with osteoporosis used calcium and vitamin D supplements, there would be an estimated 544,687 fewer fractures/year in the EU and 323,566 fewer in the US, saving over €6.9 billion and $3.9 billion; the net cost benefit would be €5,710,277,330 and $3,312,236,252, respectively.
Conclusions
Calcium and vitamin D supplements are highly cost-effective, and expanded use could considerably reduce fractures and related costs. Although these analyses included individuals aged ≥ 50 years, the observed effects are likely driven by benefits observed in those aged ≥ 65 years.
Electronic supplementary material
The online version of this article (10.1007/s11657-019-0589-y) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Cost-benefit analysis of calcium and vitamin D supplements
Connie M. Weaver; Heike A. Bischoff: Ferrari; Christopher J. Shanahan
Archives of Osteoporosis · 2019
© The Author(s) 2019https://creativecommons.org/licenses/by/4.0/Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T20:05:04.878897+00:00
DOI: 10.1007/s11657-019-0589-y · PMC6491825